Plasma melatonin is reduced in Huntington's disease

Movement Disorders

Volumn 29, Issue 12, 2014, Pages 1511-1515

  Kalliolia, Eirini ^a   Silajdžić, Edina ^b   Nambron, Rajasree ^a   Hill, Nathan R ^c   Doshi, Anisha ^a   Frost, Chris ^d   Watt, Hilary ^e   Hindmarsh, Peter ^f   Björkqvist, Maria ^b   Warner, Thomas T ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Circadian rhythm; Huntington's disease; Melatonin

Indexed keywords

BIOLOGICAL MARKER; MELATONIN;

ADULT; AGED; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HORMONE RELEASE; HUMAN; HUNTINGTON CHOREA; MALE; PRIORITY JOURNAL; SLEEP; SLEEP DISORDER; BLOOD; FOURIER ANALYSIS; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; FEMALE; FOURIER ANALYSIS; HUMANS; HUNTINGTON DISEASE; MALE; MELATONIN; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 84927523335     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26003     Document Type: Article

References (24)

1. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
2. Van der Burg J, Bjorkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol 2009;8:765-774.
3. Goodman AOG, Morton J, Barker RA. Identifying sleep disturbances in Huntington's disease using a simple disease-focused questionnaire. PLoS Curr. 2010;2:RRN1189. doi: 10.1371/currents.RRN1189.
4. Videnovic A, Leurgans S, Fan W, Jaglin J, Shannon KM. Daytime somnolence and nocturnal sleep disturbances in Huntington disease. Parkinsonism Relat Disord 2009;15:471-474.
5. Arnulf I, Nielsen J, Lohmann E, et al. Rapid eye movement sleep disturbances in Huntington disease. Arch Neurol 2008;65:482-488.
6. Wiegand M, Moller AA, Lauer CJ, et al. Nocturnal sleep in Huntington's disease. J Neurol 1991;238:203-208.
7. Morton AJ, Wood NI, Hastings MH, Hurelbrink C, Barker RA, Maywood ES. Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J Neurosci 2005;25:157-163.
8. Kudo T, Schroeder A, Loh DH, et al. Dysfunctions in circadian behavior and physiology in mouse models of Huntington's disease. Exp Neurol 2011;288:80-90.
9. Pandi-Perumal SR, Srinivasan V, Maestroni GJ, Cardinali DP, Poeggeler B, Hardeland R. Melatonin: nature's most versatile biological signal? FEBS J 2006;273:2813-2838.
10. Aziz NA, Pijl H, Frolich M, et al. Delayed onset of the diurnal melatonin rise in patients with Huntington's disease. J Neurol 2009;256:1961-1965.
11. Siesling S, van Vugt JP, Zwinderman KA, Kieburtz K, Roos RA. Unified Huntington's disease rating scale: a follow up. Mov Disord. 1998;13:915-919.
12. Leproult R, Van Onderbergen A, L'hermite-Baleriaux M, Van Cauter E, Copinschi G. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol (Oxf) 2005;63:298-304.
13. Matthews DR. Time series analysis in endocrinology. Acta Paediatr Scand Suppl 1988;347:55-62.
14. Hill NR. Analysis of non-steady state physiological and pathological processes, Thesis, University of Oxford, 2008; Available from: http://ora.ox.ac.uk/objects/ora:2356.
15. Penney JB, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997;41:689-692.
16. Christofides J, Bridel M, Egerton M, Mackay GM, Forrest CM, Stoy N, Darlington LG, Stone TW. Blood 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and melatonin levels in patients with either Huntington's disease or chronic brain injury. J Neurochem 2006;97:1078-1088.
17. Morton AJ. Circadian and sleep disorders in Huntington's disease. Exp Neurol 2013;243:33-44.
18. Loh DH, Kudo T, Truong D, Wu Y, Colwell CS. The Q175 mouse model of Huntington's disease shows gene dosage- and age-related decline in circadian rhythms of activity and sleep. Plos One 2013;8:e69993.
19. Van Wamelen DJ, Aziz NA, Anink JJ, et al. Suprachiasmatic nucleus neuropeptide expression in patients with Huntington's disease. Sleep 2013;35:117-125.
20. Wang X, Sirianni A, Pei Z, et al. The melatonin MT1 receptor axis modulates mutant Huntington-mediated toxicity. J Neurosci 2011;31:14496-507.
21. Fisher SP, Black SW, Schwartz MD, et al. Longitudinal analysis of the electroencephalogram and sleep phenotype in the R6/2 mouse model of Huntington's disease. Brain 2013;136:2159-2172.
22. Kantor S, Szabo L, Varga J, Cuesta M, Morton AJ. Progressive sleep and electroencephalogram changes in mice carrying the Huntington's disease mutation. Brain 2013;136:2147-2158.
23. Videnovic A, Noble C, Reid KJ, et al. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson's disease. JAMA Neurol 2014;71:463-469.
24. Breen DP, Vuono R, Nawarathna U, Fisher K, Shneerson JM, Reddy AB, Barker RA. Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol 2014;71:589-595.